History of IGF-1R Antibodies to treat Thyroid Eye Disease

The insulin-like growth factor-1 receptor, or IGF-1R, was initially pursued as a target for treating several forms of cancer. The research tools developed to study IGF-1R biology led to the discovery that IGF-1R is involved in Thyroid Eye Disease, leading to the clinical hypothesis that blocking IGF-1R with a monoclonal antibody could benefit TED patients.  Clinical trials proving this hypothesis has created opportunity for Viridian to advance care for TED patients by evolving IGF-1R product profiles to best meet patient needs.